透皮丁丙诺啡用于ICU大手术后疼痛控制的效果
本研究为回顾性平行队列研究,纳入2019年1月至2021年7月澳大利亚悉尼一家四级城市医院ICU收治的大胃肠或泌尿手术后患者376例,其中对照组224例(60%)、透皮丁丙诺啡组152例(40%)。采用逆概率治疗加权调整基线差异后,主要终点显著疼痛概率中位数对照组0.25 vs 透皮丁丙诺啡组0.30(中位差值0.02;95%CI 0.04-0.11;p=0.44),每日阿片消耗(口服吗啡毫克当量)中位数对照组5.7 mg vs 透皮丁丙诺啡组10.1 mg(中位差值0.4 mg;95%CI -0.4至3.7 mg;p=0.31)。结论认为,在大胃肠或泌尿手术后ICU患者中,透皮丁丙诺啡的使用与未使用相比,未改善疼痛控制或阿片消耗。
要点
- 在ICU大胃肠或泌尿手术后患者中,透皮丁丙诺啡组显著疼痛概率中位数0.30 vs 对照组0.25,中位差值0.02(95%CI 0.04-0.11;p=0.44)。
- 透皮丁丙诺啡组每日阿片消耗中位数10.1 mg口服吗啡毫克当量 vs 对照组5.7 mg,中位差值0.4 mg(95%CI -0.4至3.7 mg;p=0.31)。
- 显著疼痛定义为0-10数字评定量表≥4分或行为疼痛量表≥6分。
- 队列平均年龄60±14岁,男性202例(54%),平均急性生理与慢性健康评估III评分44±13,147例(39%)接受机械通气。
适用人群与场景
- 2019年1月至2021年7月入住澳大利亚悉尼一家四级城市医院ICU、接受大胃肠或泌尿手术后的所有患者。
- 队列376例,对照组224例(60%),透皮丁丙诺啡组152例(40%)。
诊断标准与关键阈值
- 显著疼痛评分定义为0-10数字评定量表≥4分或行为疼痛量表≥6分。
研究设计与关键结果
- 研究设计为回顾性、平行队列研究,在澳大利亚悉尼一家四级城市医院ICU进行,纳入2019年1月至2021年7月大胃肠或泌尿手术后ICU患者376例。
- 干预为透皮丁丙诺啡 vs 非透皮丁丙诺啡;采用逆概率治疗加权调整基线差异。
- 主要终点显著疼痛概率中位数:对照组0.25 vs 透皮丁丙诺啡组0.30,中位差值0.02(95%CI 0.04-0.11;p=0.44)。
- 每日阿片消耗(口服吗啡毫克当量)中位数:对照组5.7 mg vs 透皮丁丙诺啡组10.1 mg,中位差值0.4 mg(95%CI -0.4至3.7 mg;p=0.31)。
- 队列平均年龄60±14岁,男性202例(54%),平均急性生理与慢性健康评估III评分44±13,147例(39%)接受机械通气。
证据类型、等级与局限
- 证据类型:回顾性、平行队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在大胃肠或泌尿手术后入住ICU的患者中,使用透皮丁丙诺啡与未使用相比,未改善疼痛控制或阿片消耗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Transdermal buprenorphine (TBUP) may be useful for postoperative pain after major surgery, when pain is expected to be severe and sustained. The objective of this study was to compare pain control and opioid consumption in critically ill postoperative patients who were treated with TBUP or not during ICU admission.
DESIGN: This was a retrospective, parallel, cohort study.
SETTING: ICU of a quaternary, urban hospital in Sydney, Australia.
PATIENTS: Data were obtained for all patients admitted to the ICU from January 2019 to July 2021 after major gastrointestinal (GI) or genitourinary (GU) surgery.
INTERVENTIONS: TBUP or non-TBUP.
MEASUREMENTS AND MAIN RESULTS: Pain control was compared between patients who received TBUP and those who did not receive TBUP. The primary outcome was the probability of significant pain. A significant pain score was defined as greater than or equal to 4 on the 0-10 numeric rating scale or greater than or equal to 6 on the behavioral pain scale. Inverse probability of treatment weighting was used to adjust for baseline differences. The cohort included 376 patients, with 224 (60%) in the control group and 152 (40%) in the TBUP group. The mean age was 60 ± 14 years, 202 (54%) were male, mean Acute Physiology and Chronic Health Evaluation III score was 44 ± 13, and 147 (39%) received mechanical ventilation. After adjustment, the median probability of significant pain was 0.25 with control and 0.30 with TBUP (median difference, 0.02; 95% CI, 0.04-0.11; p = 0.44). The median opioid consumption (oral morphine milligram equivalents) per day was 5.7 mg with control and 10.1 mg with TBUP (median difference, 0.4 mg; 95% CI, -0.4 to 3.7 mg; p = 0.31).
CONCLUSIONS: In patients who are admitted to the ICU after major GI or GU procedures, the use of TBUP in the ICU was not associated with improved pain control or opioid consumption compared with those who did not receive TBUP.
参考来源
- Patanwala AE, Moran B, Johnstone C, et al. Effectiveness of Transdermal Buprenorphine for Pain Control in the ICU After Major Surgical Procedures. Crit Care Explor. 2022. PMID: 35372846. doi:10.1097/CCE.0000000000000665
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。